We make innovative vaccines and specialty medicines to prevent and treat disease. Our R&D focuses on the science of the immune system, human genetics and advanced technologies.
Our R&D focus is on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.
Behind the science
Discover how we're getting ahead
Eosinophils could be holding the missing link between symptoms, diagnosis and treatment
Time for a change: personalising asthma treatment
Unlocking the power of the immune system to get ahead of hepatitis B
Tackling tomorrow’s health challenges today
How vaccine science can help tackle antimicrobial resistance
The 40 year fight against HIV
How the next generation of immuno-oncology could help us get ahead of cancer
1.4 million reasons to get ahead of gynaecologic cancers
Digital twin: using advanced technology to accelerate vaccine development
What if remission were the target of lupus care?
Life at GSK
How we help people thrive
Diversity, equity and inclusion
Positively impacting society and the planet
Pricing and access
We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.
Global health and health security
We are committed to using our science, our partnerships, and the knowledge we’ve gained from addressing the world’s biggest health challenges to improve health globally.
Diversity, equity and inclusion
Our work supports the health of all kinds of people. To meet our diverse patients' needs better, we need diversity in our clinical trials and to support our own people to thrive as part of an inclusive team.
We are working towards a net zero impact on climate and a net positive impact on nature by 2030, across our full value chain.
Ensuring the quality, safety and reliable supply of our products is critical to our purpose of uniting science, talent and technology to get ahead of disease together.
In the spotlight
GSK on social
Today, at the Women’s Health Innovation Summit, our own Dr Tania Small will discuss the latest efforts to improve detection and treatment of gynaecologic cancers, and share her perspective on what is still needed to #EndCancerAsWeKnowIt.
Kim Branson, SVP for AI and Machine Learning, is featured in today’s @thetimes discussing how these technologies are helping to make GSK’s drug R&D more productive. Read more (£): thetimes.co.uk/article/ee45b2…
We’re proud to be the official Oncology Partner at this year’s Women’s Health Innovation Summit where our own Dr Tania Small will discuss efforts to accelerate progress in gynaecologic cancers as part of the greater vision to #EndCancerAsWeKnowIt. #WHISUSA
Samuel, Product Manager, Supply Chain Planning, grew up in Ghana where he witnessed first-hand the challenges faced by people needing access to essential medicines. Hear his story 👇 #AheadTogetherrh
Meet Peter, from Singapore, who is living with #multiplemyeloma. He is taking part in #BloodCancerAwarenessMonth by sharing how he finds joy and support connecting with others in the #bloodcancer community. #AheadTogether
Last week we were at #ClimateWeekNYC. We announced two new projects and shared our lessons learnt so far to help deliver a healthy planet for healthy people. Now’s the time to put health at the centre of the climate and nature conversations at #COP27 and #COP15. #AheadTogether
CEO Emma Walmsley on the appointment of Julie Brown as our next Chief Financial Officer. Read more about today’s announcement: gsk.to/3BCyPDi
#News: Iain Mackay, Chief Financial Officer (CFO), has decided to retire from GSK in May 2023. Julie Brown, currently Chief Operating and Financial Officer, Burberry Group plc, has been appointed CFO designate and an Executive Director of the Board. She joins GSK in April 2023.